Quantum Computing-Enhanced Algorithm Unveils Novel Inhibitors for KRAS
Authors:
Mohammad Ghazi Vakili,
Christoph Gorgulla,
AkshatKumar Nigam,
Dmitry Bezrukov,
Daniel Varoli,
Alex Aliper,
Daniil Polykovsky,
Krishna M. Padmanabha Das,
Jamie Snider,
Anna Lyakisheva,
Ardalan Hosseini Mansob,
Zhong Yao,
Lela Bitar,
Eugene Radchenko,
Xiao Ding,
Jinxin Liu,
Fanye Meng,
Feng Ren,
Yudong Cao,
Igor Stagljar,
Alán Aspuru-Guzik,
Alex Zhavoronkov
Abstract:
The discovery of small molecules with therapeutic potential is a long-standing challenge in chemistry and biology. Researchers have increasingly leveraged novel computational techniques to streamline the drug development process to increase hit rates and reduce the costs associated with bringing a drug to market. To this end, we introduce a quantum-classical generative model that seamlessly integr…
▽ More
The discovery of small molecules with therapeutic potential is a long-standing challenge in chemistry and biology. Researchers have increasingly leveraged novel computational techniques to streamline the drug development process to increase hit rates and reduce the costs associated with bringing a drug to market. To this end, we introduce a quantum-classical generative model that seamlessly integrates the computational power of quantum algorithms trained on a 16-qubit IBM quantum computer with the established reliability of classical methods for designing small molecules. Our hybrid generative model was applied to designing new KRAS inhibitors, a crucial target in cancer therapy. We synthesized 15 promising molecules during our investigation and subjected them to experimental testing to assess their ability to engage with the target. Notably, among these candidates, two molecules, ISM061-018-2 and ISM061-22, each featuring unique scaffolds, stood out by demonstrating effective engagement with KRAS. ISM061-018-2 was identified as a broad-spectrum KRAS inhibitor, exhibiting a binding affinity to KRAS-G12D at $1.4 μM$. Concurrently, ISM061-22 exhibited specific mutant selectivity, displaying heightened activity against KRAS G12R and Q61H mutants. To our knowledge, this work shows for the first time the use of a quantum-generative model to yield experimentally confirmed biological hits, showcasing the practical potential of quantum-assisted drug discovery to produce viable therapeutics. Moreover, our findings reveal that the efficacy of distribution learning correlates with the number of qubits utilized, underlining the scalability potential of quantum computing resources. Overall, we anticipate our results to be a stepping stone towards developing more advanced quantum generative models in drug discovery.
△ Less
Submitted 12 February, 2024;
originally announced February 2024.
Exploring the Advantages of Quantum Generative Adversarial Networks in Generative Chemistry
Authors:
Po-Yu Kao,
Ya-Chu Yang,
Wei-Yin Chiang,
Jen-Yueh Hsiao,
Yudong Cao,
Alex Aliper,
Feng Ren,
Alan Aspuru-Guzik,
Alex Zhavoronkov,
Min-Hsiu Hsieh,
Yen-Chu Lin
Abstract:
De novo drug design with desired biological activities is crucial for developing novel therapeutics for patients. The drug development process is time and resource-consuming, and it has a low probability of success. Recent advances in machine learning and deep learning technology have reduced the time and cost of the discovery process and therefore, improved pharmaceutical research and development…
▽ More
De novo drug design with desired biological activities is crucial for developing novel therapeutics for patients. The drug development process is time and resource-consuming, and it has a low probability of success. Recent advances in machine learning and deep learning technology have reduced the time and cost of the discovery process and therefore, improved pharmaceutical research and development. In this paper, we explore the combination of two rapidly-developing fields with lead candidate discovery in the drug development process. First, Artificial intelligence has already been demonstrated to successfully accelerate conventional drug design approaches. Second, quantum computing has demonstrated promising potential in different applications, such as quantum chemistry, combinatorial optimizations, and machine learning. This manuscript explores hybrid quantum-classical generative adversarial networks (GAN) for small molecule discovery. We substituted each element of GAN with a variational quantum circuit (VQC) and demonstrated the quantum advantages in the small drug discovery. Utilizing a VQC in the noise generator of a GAN to generate small molecules achieves better physicochemical properties and performance in the goal-directed benchmark than the classical counterpart. Moreover, we demonstrate the potential of a VQC with only tens of learnable parameters in the generator of GAN to generate small molecules. We also demonstrate the quantum advantage of a VQC in the discriminator of GAN. In this hybrid model, the number of learnable parameters is significantly less than the classical ones, and it can still generate valid molecules. The hybrid model with only tens of training parameters in the quantum discriminator outperforms the MLP-based one in terms of both generated molecule properties and the achieved KL divergence.
△ Less
Submitted 6 February, 2023; v1 submitted 30 October, 2022;
originally announced October 2022.
